Better Risk Perception Via Patient Similarity to Control Hyperglycemia and Sustained by Telemonitoring
NCT06607497 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360
Last updated 2026-05-12
Summary
Background: Diabetes significantly raises the likelihood of complications, thereby increasing the risk of diabetes-related mortality, particularly due to vascular complications. It is vital to address this rising trend of mortality, by enhancing awareness of diabetes complications to improve risk perception and ultimately reduce mortality rates. Managing diabetes effectively requires interventions addressing both risk communication and monitoring, helping patients better understand and make informed decisions about their health.
Objectives: The primary aim is to evaluate and compare the effectiveness of combined risk communication session using an AI module (PERDICT.AI) and home-based diabetes monitoring (PTEC-DM) versus a standalone risk communication session in improving health outcomes (risk perception, medication adherence, self-care activities and glycaemic control) among poorly controlled diabetes patients. Secondary aims are to explore participants' views and experiences of risk communication session using PERDICT.AI, PTEC-DM and usual care and clinician' views on utility of the new approach to improve risk perception.
Methods: A mixed-method study design will be employed to conduct a multi-arm randomized controlled trial across four of the SingHealth Polyclinics cluster (Pasir Ris, Eunos, Sengkang, Tampines North). Patient participants will be randomly allocated in a 1:1:1 ratio to one of the three arms. Arm 1 will receive risk communication session using PERDICT.AI and home-based diabetes monitoring using PTEC-DM alongside usual care. Arm 2 participants will undergo a standalone risk communication session using PERDICT.AI with usual care while arm 3 will serve as the control group with usual care. A total of 360 (120 in each group) participants will be enrolled by simple randomization. Eligible patient must be of age between 36 and 65 years with HbA1c \>8.0% within the last 6 months.
Significance of the study: Findings from the study may add evidence to the scientific knowledge of using these approaches to improve risk perception and recommend development of similar interventions.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- OTHER
-
Intervention using an AI enabled risk communication tool (PERDICT.AI)
Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
- OTHER
-
Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)
The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
Sponsors & Collaborators
-
AISG Health Grand Challenge
collaborator UNKNOWN -
SingHealth Polyclinics
lead OTHER
Principal Investigators
-
Ngiap Chuan Tan, MMed · SingHealth Polyclinics
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 36 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-15
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Singapore
Study Locations
More Related Trials
-
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
NCT04304261 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China
NCT07338552 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Self-Care for Older People With Diabetes Mellitus
NCT03890991 ·Status: UNKNOWN ·Phase: NA
-
DETECT-Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment
NCT01076608 ·Status: COMPLETED
-
Determination of the Optimum Cut-off Value of Type 2 Diabetes Diagnosis Among Chinese Population(SENSIBLE STUDY II)
NCT03024788 ·Status: UNKNOWN
-
SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
NCT05256706 ·Status: COMPLETED ·Phase: NA
-
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
NCT05770687 ·Status: RECRUITING
-
The DIAMOND® for the Treatment of Type 2 Diabetes
NCT02079376 ·Status: UNKNOWN ·Phase: NA
-
Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control
NCT05651490 ·Status: UNKNOWN ·Phase: NA
-
Cohort Study in Type 2 Diabetes in China
NCT01076023 ·Status: UNKNOWN
-
Personalized Medicine for Diabetes Prediction and Prevention of Complications
NCT01268813 ·Status: UNKNOWN ·Phase: PHASE1
-
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
NCT03707171 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Remote SMBG Combined With the Application of APP on the Improvement of T2DM Management in the Community
NCT03588000 ·Status: COMPLETED ·Phase: NA
-
An Evaluation of the Effectiveness and Acceptability of Delivering Structured Care in Chinese Type 2 Diabetic Patients
NCT01360697 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by a Diabetes Specialist Team
NCT01690208 ·Status: UNKNOWN ·Phase: NA
-
Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes
NCT03558867 ·Status: COMPLETED ·Phase: NA
-
Precision Medicine in Chinese Patients With Young Onset Diabetes
NCT04049149 ·Status: UNKNOWN ·Phase: NA
-
Precision Diabetes Management: Integrated East-West Approach
NCT07307040 ·Status: NOT_YET_RECRUITING
-
Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM)
NCT00814190 ·Status: COMPLETED ·Phase: NA
-
Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes
NCT05980754 ·Status: NOT_YET_RECRUITING
-
Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis
NCT06060483 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
NCT07198191 ·Status: ACTIVE_NOT_RECRUITING
-
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
NCT05313529 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
NP-Supported Multidisciplinary Diabetes Management During Perioperative Period
NCT05293015 ·Status: UNKNOWN ·Phase: NA
-
Stressors, Coping Methods and Social Support in Diabetic Patients
NCT01159184 ·Status: COMPLETED